At the time of writing, Immix Biopharma Inc [IMMX] stock is trading at $2.51, up 11.80%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IMMX shares have gain 20.10% over the last week, with a monthly amount glided 15.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
For the past year, the stock price of Immix Biopharma Inc fluctuated between $1.34 and $3.20. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Immix Biopharma Inc [NASDAQ: IMMX] shares were valued at $2.51 at the most recent close of the market. An investor can expect a potential return of 178.88% based on the average IMMX price forecast.
Analyzing the IMMX fundamentals
Gross Profit Margin for this corporation currently stands at -1.21% with Operating Profit Margin at -246.99%, Pretax Profit Margin comes in at -239.75%, and Net Profit Margin reading is -240.18%. To continue investigating profitability, this company’s Return on Assets is posted at -1.48, Equity is -2.05 and Total Capital is -4.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.31 points at the first support level, and at 2.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.66, and for the 2nd resistance point, it is at 2.82.
Ratios To Look Out For
It is important to note that Immix Biopharma Inc [NASDAQ:IMMX] has a current ratio of 1.23. In addition, the Quick Ratio stands at 1.23 and the Cash Ratio stands at 1.16.
Transactions by insiders
Recent insider trading involved Rachman Ilya M, CEO and Chairman, that happened on Sep 17 ’25 when 2500.0 shares were purchased. CFO, Morris Gabriel S completed a deal on Sep 16 ’25 to buy 2600.0 shares. Meanwhile, CEO and Chairman Rachman Ilya M bought 2178.0 shares on Jun 18 ’25.
